C-reactive protein and cancer—diagnostic and therapeutic insights
PC Hart, IM Rajab, M Alebraheem… - Frontiers in …, 2020 - frontiersin.org
Cancer disease describes any pathology involving uncontrolled cell growth. As cells
duplicate, they can remain localized in defined tissues, forming tumor masses and altering …
duplicate, they can remain localized in defined tissues, forming tumor masses and altering …
G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
N Arang, JS Gutkind - FEBS letters, 2020 - Wiley Online Library
G protein‐coupled receptors (GPCRs) and heterotrimeric G proteins play central roles in a
diverse array of cellular processes. As such, dysregulation of GPCRs and their coupled …
diverse array of cellular processes. As such, dysregulation of GPCRs and their coupled …
m6A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
An impressive clinical success has been observed in treating a variety of cancers using
immunotherapy with programmed cell death‐1 (PD‐1) checkpoint blockade. However …
immunotherapy with programmed cell death‐1 (PD‐1) checkpoint blockade. However …
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 …
SB Goldberg, KA Schalper, SN Gettinger… - The Lancet …, 2020 - thelancet.com
Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …
Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing
Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell …
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell …
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …
Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade
Purpose: Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4)
correlate with the extent of tumor immune infiltrate, but the mechanisms underlying the …
correlate with the extent of tumor immune infiltrate, but the mechanisms underlying the …
Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study
EJ Lampert, A Zimmer, M Padget… - Clinical Cancer …, 2020 - AACR
Purpose: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory
micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade …
micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade …
Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion
H Luo, J Su, R Sun, Y Sun, Y Wang, Y Dong, B Shi… - Clinical Cancer …, 2020 - AACR
Purpose: T-cell recruitment, survival, and proliferation are the important limitations to
chimeric antigen receptor (CAR) T cells therapy in the treatment of solid tumors. In this study …
chimeric antigen receptor (CAR) T cells therapy in the treatment of solid tumors. In this study …
Learning from clinical trials of neoadjuvant checkpoint blockade
Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a
promising new approach to managing bulky but resectable melanoma, and is also being …
promising new approach to managing bulky but resectable melanoma, and is also being …